This approach generates functional T cells in murine models, indicating potential for immunotherapy applications.
Thymic function can decline due to age-related involution, congenital disorders, acute infections, or chemo/radiation therapy. Decline in thymic function leads to decreased T cell production and weakened immunity. To address these thymic insufficiencies, we aimed to develop a transplantable and scalable micro-organoid system utilizing fibroblasts and thymic cells. We have developed a reliable and rapid method to generate thymic micro-organoids using selectively screened fibroblasts and murine thymic cells. The thymic micro-organoids are cryo-preservable, injectable, and give rise to T cells both in vitro and in vivo . Thymic organoids expressed key genes required to sustain T cell development and maturation: ccl25, dll-1, dll-4, foxn-1, il-7, scf . When injected into T cell-deficient Prkdc scid mice, the organoids gave rise to functional αβ, ψ8, natural killer T (NKT) cells, and FoxP3 + regulatory T cells. Organoid-derived T cells expressed a diverse T cell receptor (TCR) repertoire i n vivo and responded to stimulation with anti-CD3/28, Concanavalin-A, or Phytohemagglutinin. Thymic organoids derived from pmel-1 thymocytes gave rise to Vβ13 + T cells that delayed the growth of B16 melanoma and enhanced activation of T and NK cells. This approach presents a valuable tool for mechanistic studies and addressing current therapeutic gaps in diseases associated with thymic decline and insufficiencies.
No takes yet. Share an insight, caveat, or question.
Gebremeskel et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: